# Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

> **NCT01381471** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 11060 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol xinafoate combination

## Key facts

- **NCT ID:** NCT01381471
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2010-05
- **Final completion:** 2010-05
- **Target enrollment:** 11060 (ACTUAL)
- **Last updated:** 2012-03-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01381471

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01381471, "Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01381471. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*